Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620648
Title:
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.
Authors:
Buzzoni, R; Carnaghi, C; Strosberg, J; Fazio, N; Singh, S; Herbst, F; Ridolfi, A; Pavel, M; Wolin, E; Valle, Juan W ( 0000-0002-1999-0863 ) ; Oh, D; Yao, J; Pommier, R
Abstract:
Recently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35-0.67; P<0.00001) in the Phase III, RADIANT-4 study. This post hoc analysis evaluates the impact of prior therapies (somatostatin analogs [SSA], chemotherapy, and radiotherapy) on everolimus activity.
Affiliation:
IRCCS Foundation, National Institute of Tumors, Milan, Italy
Citation:
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. 2017, 10:5013-5030 Onco Targets Ther
Journal:
OncoTargets and Therapy
Issue Date:
2017
URI:
http://hdl.handle.net/10541/620648
DOI:
10.2147/OTT.S142087
PubMed ID:
29081664
Type:
Article
Language:
en
ISSN:
1178-6930
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBuzzoni, Ren
dc.contributor.authorCarnaghi, Cen
dc.contributor.authorStrosberg, Jen
dc.contributor.authorFazio, Nen
dc.contributor.authorSingh, Sen
dc.contributor.authorHerbst, Fen
dc.contributor.authorRidolfi, Aen
dc.contributor.authorPavel, Men
dc.contributor.authorWolin, Een
dc.contributor.authorValle, Juan Wen
dc.contributor.authorOh, Den
dc.contributor.authorYao, Jen
dc.contributor.authorPommier, Ren
dc.date.accessioned2017-11-21T21:59:34Z-
dc.date.available2017-11-21T21:59:34Z-
dc.date.issued2017-
dc.identifier.citationImpact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. 2017, 10:5013-5030 Onco Targets Theren
dc.identifier.issn1178-6930-
dc.identifier.pmid29081664-
dc.identifier.doi10.2147/OTT.S142087-
dc.identifier.urihttp://hdl.handle.net/10541/620648-
dc.description.abstractRecently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35-0.67; P<0.00001) in the Phase III, RADIANT-4 study. This post hoc analysis evaluates the impact of prior therapies (somatostatin analogs [SSA], chemotherapy, and radiotherapy) on everolimus activity.en
dc.language.isoenen
dc.rightsArchived with thanks to OncoTargets and therapyen
dc.titleImpact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.en
dc.typeArticleen
dc.contributor.departmentIRCCS Foundation, National Institute of Tumors, Milan, Italyen
dc.identifier.journalOncoTargets and Therapyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.